Phosphagenics and US agency target cow infection
15 May, 2013 by Dylan Bushell-EmblingPhosphagenics (ASX:POH) and a US Department of Agriculture research agency will jointly formulate and test products aimed at fighting the bacterial infection mastitis in dairy cows.
REVA appoints new managing director
15 May, 2013 by Dylan Bushell-EmblingMichel Vanbrabant will joint REVA Medical (ASX:RVA) as managing director to help the company prepare its EU market strategy for bioresorbable coronary scaffold ReZolve2.
pSivida posts $2.8m loss for Q3
15 May, 2013 by Dylan Bushell-EmblingpSivida (ASX:PVA) says its net loss grew slightly in Q3, as it awaits revenue and royalty payments from partner Alimera for the Iluvien insert.
Mercury Capital invests in Novotech
14 May, 2013 by Dylan Bushell-EmblingPE firm Mercury Capital has acquired a 30% stake in incumbent Australian CRO Novotech, with the option to increase its holding to 50%.
Bioniche to sell animal health division
14 May, 2013 by Dylan Bushell-EmblingBioniche (ASX:BNC) has hired an adviser to help it negotiate a sale of its animal health division and has received two preliminary partnership offers for bladder cancer treatment Urocidin.
AusBiotech secures Australian first with world brain mapping congress
14 May, 2013AusBiotech is pleased to announce that the 11th Annual World Congress of the Society for Brain Mapping and Therapeutics (SBMT) will be held in Australia for the first time in March 2014.
AU boffins develop bacteria-killing Trojan horse
13 May, 2013 by Dylan Bushell-EmblingScientists from UOW and UNSW have patented a new drug technology for combating antibiotic-resistant bacteria, developed by thinking like the enemy.
Starpharma dendrimer effective against adenovius
13 May, 2013 by Dylan Bushell-EmblingStarpharma (ASX:SPL) said its lead dendrimer candidate has shown potential as the first treatment for adenovirus, the primary cause of viral conjunctivitis.
BioDiem moves to animal trials in pneumocystosis
13 May, 2013 by Dylan Bushell-EmblingBioDiem (ASX:BDM) has said its antimicrobial candidate BDM-I is ready for preclinical trials against Pneumocystosis, a parasitic fungus that can cause pneumonia.
Cellmid to buy Advangen Japan in $4m deal
10 May, 2013 by Dylan Bushell-EmblingCellmid (ASX:CDY) will pay around $4m in cash and stock to acquire Advangen Japan and, with it, the hair growth technology platform behind Cellmid’s evolis line.
New member for Prima board
09 May, 2013 by Susan Williamson and Dylan Bushell-EmblingPrima Biomed (ASX: PRR) has announced a new board member, Dr Russell Howard.
Bioniche in talks to boost cash reserves
09 May, 2013 by Dylan Bushell-EmblingBioniche (ASX:BNC) is in talks with its lender to address a looming cash shortage and consulting with advisers to address the “challenges” posed by a group of dissident shareholders.
Concern over NSW indemnity insurance impact on clinical trials prompts survey
09 May, 2013Members of AusBiotech are invited to participate in a survey to gauge the impact of the 2011 increase in the Clinical Trial Indemnity Insurance Compliance Requirement.
Iluvien launches in Germany
08 May, 2013 by Dylan Bushell-EmblingpSivida (ASX:PVA) licensee Alimera Sciences has followed up the launch of DME treatment Iluvien in the UK with the first commercial sale in Germany.
Novogen appoints new CSO
07 May, 2013 by Dylan Bushell-EmblingNovogen (ASX:NRT) has announced two new executive appointments - a CSO, as well as a president and CEO of its new North American subsidiary.
